Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Phase III Chemotherapy with NM/VCR/PCB/PRED and Low-Dose BLEO for Hodgkin's Disease Stages IIIB, IVA and IVB

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III

Treatment

Closed

no age specified

NCI

SWOG-774/775

Objectives

I.  Determine the effectiveness of MOPP (nitrogen mustard, vincristine, 
procarbazine, prednisone) alone and in combination with low-dose bleomycin for 
complete remission induction in patients with disseminated Hodgkin's disease 
(stages IIIB, IVA, IVB).
II.  Determine the relative effectiveness of MOPP and radiation therapy (to 
the area of major disease involvement prior to MOPP) followed by MOPP and more 
intensive MOPP dosage schedule for remission consolidation in those patients 
achieving complete remission.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with demonstrable stages 
IIIB, IVA, or IVB Hodgkin's disease.  Patients must have adequate bone marrow 
reserve.

Expected Enrollment

Protocol closed 08/74.

Outline

Randomized study.
Induction:  Nonrandomized treatment.
Enter patients with compromised pulmonary function to Arm I, enter all other 
patients to Arm II (Amendment 2, June, 1973).
Arm I:  3-Drug Combination Chemotherapy and Hormone Therapy (MOPP).  Nitrogen 
mustard, NM, NSC-762; Vincristine, VCR, NSC-67574; Procarbazine, PCB, 
NSC-77213; Prednisone, PRED, NSC-10023.
Arm II:  3-Drug Combination Chemotherapy and Hormone Therapy with MOPP.  NM; 
VCR; PCB; PRED; plus low-dose Bleomycin, BLEO, NSC-125066.
Consolidation.  Randomized treatment.  Randomize patients with complete 
remission to Arms III, IV and V.
Arm III:  3-Drug Combination Chemotherapy and Hormone Therapy with MOPP.  NM; 
VCR; PCB; PRED.
Arm IV:  Radiotherapy followed by 3-Drug Combination Chemotherapy and Hormone 
Therapy with MOPP.  NM; VCR; PCB; PRED.
Arm V:  Intensive 3-Drug Combination Chemotherapy and Hormone Therapy with 
MOPP.  NM; VCR; PCB; PRED.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Charles Coltman, MD, Protocol chair(Contact information may not be current)
Ph: 210-567-2710

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.